Evidence map›Paper›PMID 36338145›Full record

ArticleOncoimmunology2022

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy.

Xinxin Song, Zhuan Zhou, Rui Kang, Daolin Tang

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Xinxin SongDepartment of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA.
Zhuan ZhouDepartment of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA.
Rui KangDepartment of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA.
Daolin TangDepartment of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0002-1903-6180

Funding

Targeting HMGB1-mediated Autophagy in Cancer TherapyR01CA160417 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TANG, DAOLIN · 2012 to 2023
$3.0M
Mechanisms of Ferroptotic Cancer Cell DeathR01CA229275 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TANG, DAOLIN · 2019 to 2024
$1.8M
The Pancreatic Cancer MicroenvironmentR01CA211070 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI KANG, RUI · 2017 to 2023
$1.4M
6 · The paper itself

Abstract

The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selectively eliminate G12Ci-resistant cells.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsCell Line, TumorHumansMutationProto-Oncogene Proteins p21(ras)T-LymphocytesKRAS protein, humanProto-Oncogene Proteins p21(ras)bispecific T cell engagersKRAS-G12C

Identifiers

PMID36338145
PMCPMC9629117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.